In a phase 2, multicenter, placebo-controlled, double-blind, parallel-group clinical trial, golimumab treatment resulted in increased insulin production and less exogenous insulin use among children and young adults with newly diagnosed overt T1D (24). This evidence concerns the gene INS and type 1 diabetes mellitus.